Collagen Mimetic Peptide Conjugates for Targeted Therapeutic Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing drug delivery systems are inefficient, costly, and often cause deleterious effects due to non-targeted administration of therapeutic compounds, leading to higher dosages and reduced patient compliance, while medical devices for wound healing lack targeted and rapid recovery mechanisms.
Innovation Solution
Conjugation of therapeutic compounds to collagen mimetic peptides (CMPs) to create targeted drug delivery systems and medical devices that facilitate rapid healing and recovery by delivering therapeutic compounds directly to the site of affliction.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional non-targeted drug delivery systems are used, then therapeutic compounds can be administered systemically, but dosage requirements increase and deleterious effects occur due to non-specific distribution
Solution Approach 1:
The patent applies local quality by modifying specific regions of the collagen molecule to create targeted binding sites. The collagen is engineered with specific amino acid sequences and structural modifications that enable selective binding to target tissues, ensuring that therapeutic compounds are delivered only where needed rather than distributed systemically throughout the body.
Solution Approach 2:
The patent uses collagen as an intermediary carrier molecule that mediates between the therapeutic compound and the target tissue. The collagen structure serves as a delivery vehicle that binds therapeutic compounds and transports them to specific locations, reducing non-specific distribution and associated harmful effects.
2Quantity of substance
If higher dosages are administered to overcome non-targeted delivery inefficiency, then treatment coverage improves, but patient compliance decreases due to increased side effects
Solution Approach 1:
The patent segments the delivery function by separating the therapeutic compound from non-targeted distribution through collagen-mediated targeted delivery. This segmentation allows lower dosages to achieve the same effective delivery to target tissues, reducing side effects and improving patient compliance.
3Productivity
If conventional wound healing devices are used, then basic wound coverage is provided, but rapid healing and recovery are not achieved due to lack of targeted therapeutic delivery
Solution Approach 1:
The patent merges the wound healing device with targeted therapeutic delivery functionality by incorporating collagen-based delivery systems into the device structure. This integration enables the device to not only provide physical wound coverage but also deliver therapeutic compounds directly to the wound site, accelerating healing without requiring separate complex delivery systems.
Data Source
AI summary
The present invention is in the fields of medicinal chemistry, biotechnology and pharmaceuticals. The invention provides compositions comprising one or more collagen mimetic peptides, optionally attached to one or more therapeutic compounds or one or more imaging compounds, for use in methods of treating, preventing, ameliorating, curing and diagnosing certain diseases and physical disorders in humans and veterinary animals, as well as methods of manufacturing such composition. The invention also provides medical devices comprising one or more such compositions of the invention. The invention also provides methods of use of such compositions and devices in treating and diagnosing certain diseases and physical disorders in humans and veterinary animals, including ocular diseases or disorders, skin diseases or disorders, certain cancers, particularly intraluminal cancers, gastrointestinal diseases or disorders, genitourinary tract diseases or disorders, fibrotic diseases/disorders and rheumatic diseases/disorders.